Zosurabalpin
Medium EvidenceA first-in-class tethered macrocyclic peptide antibiotic that kills carbapenem-resistant Acinetobacter baumannii (CRAB) by blocking the bacterium's lipopolysaccharide (LPS) transporter, now advancing into a global Phase 3 trial.
What It Is
Zosurabalpin (RG6006), developed by Roche, is a tethered macrocyclic peptide (MCP) antibiotic and the first of an entirely new structural and mechanistic class of antibiotics to reach late-stage clinical development in decades. It was discovered by screening roughly 45,000 compounds and is built around a macrocyclic peptide scaffold tethered to a small-molecule warhead. Unlike the GLP-1, growth-hormone or healing peptides that dominate consumer interest, zosurabalpin is an investigational pathogen-specific antibiotic designed for one of the most dangerous drug-resistant superbugs: carbapenem-resistant Acinetobacter baumannii (CRAB), which the World Health Organization classifies as a critical-priority pathogen for which new treatments are urgently needed. Its mechanism is novel: it binds and traps the LptB2FGC complex, the molecular machine that ferries lipopolysaccharide (LPS) from the inner membrane to the outer membrane of Gram-negative bacteria. By jamming this transporter, zosurabalpin causes toxic LPS to accumulate inside the cell, collapsing outer-membrane assembly and killing the bacterium. Because this target and binding site are unrelated to those of existing antibiotics, zosurabalpin is not affected by the resistance mechanisms that defeat carbapenems and most other current drugs. Its discovery and structural mechanism were detailed in two back-to-back papers published in Nature in January 2024 by scientists at Roche and Harvard. In preclinical work it was highly potent against human clinical CRAB isolates and cleared lung and thigh infections in mice caused by pan-drug-resistant A. baumannii; Phase 1 studies in healthy volunteers supported its safety, tolerability and pharmacokinetics. In 2025-2026 Roche moved zosurabalpin into a global Phase 3 program (roughly 400 hospitalized patients with serious CRAB infections), making it one of the most closely watched antibiotics in development. It is an intravenous, hospital-use investigational drug, not an approved or self-administered research peptide.
Regulatory Status
Zosurabalpin (RG6006, Roche) is an investigational antibiotic that has completed Phase 1 and is advancing into a global Phase 3 trial (announced 2025, initiating late 2025/2026) in hospitalized patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. It is not approved by any regulator and is administered intravenously in a hospital setting; it is not available as a research or self-experimentation peptide.
Effective: June 2026
View FDA SourceWhy Researchers Study It
Zosurabalpin is studied as the leading proof that an entirely new antibiotic class can be designed against a target — the bacterial LPS transporter (LptB2FGC) — that no marketed drug exploits. Carbapenem-resistant Acinetobacter baumannii is a WHO critical-priority pathogen that causes life-threatening hospital-acquired pneumonia and bloodstream infections with few remaining treatment options, so a first-in-class agent unaffected by existing resistance is a major unmet-need target. Researchers are interested in its tethered-macrocyclic-peptide chemistry as a template for reaching difficult Gram-negative targets, in its pathogen-specific (narrow-spectrum) strategy that spares the microbiome, and in whether its preclinical and Phase 1 promise will translate into a Phase 3 cure of serious CRAB infections.
Proposed Mechanisms
- Binds and traps the LptB2FGC complex, the inner-membrane transporter that exports lipopolysaccharide (LPS) toward the outer membrane in Gram-negative bacteria
- Blocks LPS transport, causing toxic LPS to accumulate inside the bacterial cell
- Disrupts outer-membrane biogenesis, which Acinetobacter baumannii depends on for viability and barrier function
- Acts as a tethered macrocyclic peptide (MCP) — a macrocyclic peptide scaffold linked to a small-molecule warhead — representing a new antibiotic structural class
- Targets a binding site unrelated to existing antibiotics, so it evades carbapenem and other established resistance mechanisms
- Pathogen-specific (narrow-spectrum) activity focused on the Acinetobacter baumannii-calcoaceticus complex rather than broad-spectrum killing
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Mechanism / structural biology (Nature 2024) | Biochemical and cryo-EM studies of the LptB2FGC LPS transporter | Positive: defined a novel antibiotic class that kills A. baumannii by trapping the LPS transporter; two back-to-back Nature papers (Roche/Harvard), January 2024 | Source |
| Preclinical (in vitro + animal) | Human clinical CRAB isolates; mouse lung and thigh infection models (pan-drug-resistant A. baumannii) | Positive: potent activity against carbapenem-resistant isolates and clearance of infection in mice; unaffected by pre-existing resistance mechanisms | Source |
| Clinical (Phase 1, healthy volunteers) | Single-dose safety, tolerability and pharmacokinetics in healthy participants (NCT05614895) | Supportive: safety, tolerability and PK supported continued development | Source |
| Clinical (Phase 3, initiating) | ~400 hospitalized patients with serious carbapenem-resistant A. baumannii infections vs standard of care; global sites | Pending: pivotal efficacy/safety trial announced 2025, initiating late 2025/2026 | Source |
Commonly Discussed Benefits
Researching Zosurabalpin? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- An investigational, unapproved antibiotic still in clinical trials — efficacy and safety in patients are not yet established and it is not available outside trials
- Intravenous, hospital-administered drug for serious infections under specialist (infectious-disease) care — not a self-experimentation or wellness peptide
- Narrow-spectrum and pathogen-specific: intended only for confirmed or strongly suspected Acinetobacter baumannii infection, not general antibacterial use
- Human side-effect profile is still being characterized; Phase 3 will define tolerability, dosing and any organ-specific risks
- As with any new antibiotic, real-world resistance could emerge over time and must be monitored
- Any claims of antimicrobial benefit from unregulated 'research' sources are unsupported — the only legitimate access is through controlled clinical trials
Comparisons
See how Zosurabalpin compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Roche to launch phase 3 trial for new antibiotic targeting Acinetobacter baumannii — CIDRAP (2025/2026) PubMed
- [2] A novel antibiotic class targeting the lipopolysaccharide transporter — Nature 2024 (Zampaloni et al.), PMC PubMed
- [3] Zosurabalpin: a novel tethered macrocyclic peptide antibiotic that kills carbapenem-resistant Acinetobacter baumannii — review (PMC) PubMed
- [4] Safety, Tolerability, and PK of single-dose zosurabalpin in healthy participants — Phase 1 (PMC) PubMed
- [5] Novel antibiotic class shows promise against carbapenem-resistant Acinetobacter — CIDRAP PubMed
Keep researching in the app
- Log Zosurabalpin to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
KPV
Medium EvidenceA tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties.
LL-37
Medium EvidenceA human antimicrobial peptide studied for innate immunity, wound healing, and biofilm disruption.
AI-Discovered Antimicrobial Peptides
Medium EvidenceA new class of antimicrobial peptides discovered and optimized using artificial intelligence platforms, with over 79 active compounds identified from a catalog of 863,498 AI-predicted sequences showing efficacy against multidrug-resistant pathogens.
Zilucoplan
High EvidenceA self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis.